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Case Report
Successful Graft Recovery from Thrombotic Acute Kidney Injury in a 
Kidney Transplant Patient with Antiphospholipid Syndrome
Younjeong Choi, M.D.1, Hyewon Lee, M.D.1, Yujung Yun, M.D.1, Youngki Lee, M.D.1, 
Eudong Hwang, M.D.1, Hyeonjoo Jeong, Ph.D.2 and Beom Seok Kim, Ph.D.1
Departments of Internal Medicine1 and Pathology2, Yonsei University College of Medicine, Seoul, Korea
Antiphospholipid syndrome nephropathy (APSN) is well documented in the literature as the renal involvement of the 
antiphospholipid syndrome (APS). A review of literature also shows that among antiphospholipid antibodies, lupus 
anticoagulant (LA) positivity is recognized as the strongest risk factor for APSN. In addition, APSN is also known to be 
associated with a poor functional outcome in the first posttransplant year. Therefore, it is a general belief that renal 
transplantation may be life threatening in APS patients. Furthermore, the presence of LA at the time of transplantation is 
particularly associated with a high rate of allograft APSN and the consequent poor transplantation outcomes. Here, we report 
the case that thrombotic acute kidney injury due to APSN after kidney transplantation can be successfully treated if 
anticoagulation therapy is timely applied with a prompt diagnosis.
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Introduction
The antiphospholipid syndrome (APS) describes a 
clinical entity with recurrent thrombosis, fetal loss and 
the presence of antiphospholipid antibodies (APAs)(1). 
Antiphospholipid syndrome nephropathy (APSN) is the 
renal involvement of the APS(2). The most frequently 
observed pathologic lesions are the thrombotic micro-
angiopathy (TMA), characterized by the fibrin thrombi 
in glomeruli and/or arterioles in the absence of vas-
cular immune deposits or inflammatory cells and more 
chronic vascular lesions such as fibrous intimal hyper-
plasia (FIH) of interlobular arteries, and focal cortical 
atrophy (FCA)(2,3). APSN is usually associated with 
grave functional outcome in the first posttransplant 
year(4). So renal transplantation may be life-threat-
ening in APS patients, and the presence of lupus anti-
coagulant (LA) at the time of transplantation is asso-
ciated with a high rate of allograft APSN and poor 
transplantation outcome(3,4). Here we introduce the 
case that thrombotic acute kindey injury from APSN 
after kidney transplantation can be successfully treated 
if anticoagulation therapy is timely applied with 
prompt diagnosis.
Case Report
A 25-year-old woman was diagnosed lupus nephritis 
(class IV) in 2004. Despite of recurrent immunosu-
ppressive treatment (steroid, cyclophosphamide, ritux-
imab, and mycophenolate), her renal function had 
been decreased. Finally she was diagnosed end-stage 
renal disease and started hemodialysis from December 
2010. Kidney transplantation was planned and while 
doing the preoperative evaluation right atrium myx-
oma was suspected in transesophageal echocardiog-
raphy on May 16, 2011. Removal via submammarial 
incision was conducted and organizing thrombus was 
found, thus coumadinization was started (Fig. 1). She 
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Fig. 2. The biopsy slide of trans-
planted kidney showing cortical 
necrosis, focal (postoperative day 
8) (A, HE stain, ×120; B, PAS stain,
×120).
Fig. 3. Sonography of transplanted
kidney (postoperative day 15). The
transplanted kidney size was 11.4 
cm. The echogenicity of the cortex 
was increased and blood flow was
decreased. The resistive index of 
upper, mid, and lower pole was 
0.56.
Fig. 1. Echocardiogram showing 
right atrium thrombus. After re-
moval via submammrial incision, 
thrombus was disappeared.
was hospitalized on September 3, 2011, had heparin 
5,000 unit subcutaneous injection daily for 3 days and 
stopped the day before the operation. On September 
7, 2011 (day 0) she had living-related kidney trans-
plantation from her cousin. Immumosuppressive ther-
apy consisted of prednisolone, mycophenolate, and 
tacrolimus. Heparin 5,000 unit subcutaneous injection 
daily was started again on day 2. Doppler Ultrasono-
graphy on the graft proceeded on day 3, and cortical 
echogenicity was in normal range. But serum crea-
tinine (sCr) level was elevated continuously (5.16 
mg/dL). Empirical steroid pulse therapy for acute re-
jection was done on day 3. In the Doppler ultra-
sonography on day 7, echogenicity of cortex slightly 
increased as well as the blood flow to the graft de-
creased. So graft biopsy was performed on day 8. 
Two-third of renal cortex showed ischemic necrosis 
and the remaining parenchyma showed tubular ne-
crosis and interstitial edema (Fig. 2). APA was ana-
lyzed: LA (+), anticardiolipin antibody (aCL) immunog-
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Fig. 5. Sonography of transplanted kidney (postoperative day 3 months). The transplanted kidney size was 11.8 cm. The echogenicity
of the cortex was normal and there was no hydronephrosis was no hydronephrosis or fluid collection. The resistive index of upper, 
mid, and lower pole was 0.60∼0.64.
Fig. 4. Change of renal function. After anticoagulation therapy
was started the transplanted kidney function was improved. 
Abbreviations: eGFR, epidermal growth factor receptor; POD, 
postoperative day.
lobulin M (IgM) (-), aCL IgG (-), anti-β2GP1(aβ2GP1) 
IgG (-), and aβ2GP1 IgM (-). With the diagnosis of 
APSN, anticoagulation therapy was continued. From 
day 10, 5,000 unit of heparin was subcutaneously in-
jected twice a day. Since then, sCr decreased con-
tinuously. In the Doppler ultrasonography on day 15, 
echogenicity of allograft cortex still increased, however 
the blood flow to the graft was improved (Fig. 3). 
Heparin was changed to coumadin with target pro-
thrombin time international normalized ratio 2∼3. 
Finally on day 25 sCr was decreased to 1.64 mg/dL 
(Fig. 4). After 12 weeks, LA was weak positive and 
sCr was 1.28 mg/dL. Doppler ultrasonography per-
formed 3 months after transplantation showed the nor-
mal echogenicity of the cortex and improved blood 
flow (Fig. 5). She takes coumadin currently without 
additional complications.
Discussion
The manifestations of APSN are the renal artery 
thrombosis/stenosis, renal infarction, hypertension, re-
nal vein thrombosis, end-stage renal disease, increased 
allograft vascular thrombosis, some types of glomerular 
disease, and a small vessel vaso-occlusive nephrop-
athy(2). The most frequently observed pathologic le-
sions are the TMA, characterized by the fibrin thrombi 
in glomeruli and/or arterioles in the absence of vas-
cular immune deposits or inflammatory cells and more 
chronic vascular lesions such as FIH of interlobular ar-
teries, and FCA(2,3).
In APSN, APAs are directed against phospholipid- 
protein complexes and include LA, IgG or IgM aCL, 
and IgG or IgM aβ2GPI(1,2). Antibodies should be 
demonstrable on at least two occasions separated by 
12 weeks(1). These antibodies may be associated with 
connective tissue diseases such as systemic lupus er-
ythematosus (secondary APS) or be found in isolation 
(primary APS)(5). However, the most recent interna-
tional consensus statement on classification criteria for 
APS advises against this terminology because the clin-
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ical consequences in both groups appear to be the 
same(5).
Among APAs, LA positivity is recognized as the 
strongest risk factor for APSN(2). And APSN is asso-
ciated with grave functional outcome in the first post-
transplant year(4). So renal transplantation may be 
life-threatening in APS patients, and the presence of 
LA at the time of transplantation is associated with a 
high rate of allograft APSN and poor transplantation 
outcome(3,4).
In this case, the APA status had not been worked 
up before the kidney transplantation. Although throm-
bus was not found in the pathology, evidence of vas-
cular obstruction and decreased blood flow from 
Doppler ultrasonography suggested the high proba-
bility of thrombotic lesion. Considering the previous 
history of atrial thrombus and the serologic evidence, 
we concluded that APS involved the grafted kidney in 
this case. The improved blood flow of the grafted kid-
ney after 3 months with continuous anticoagulation 
therapy also suggested the APSN. APSN is usually as-
sociated with a catastrophic functional outcome in the 
first posttransplant year(5). However in our case, renal 
function was improved dramatically with the appro-
priate anticoagulation therapy after the early detection 
of allograft APSN. Our experience suggests that kidney 
transplantation can be performed successfully in APS 
patients if timely anticoagulation therapy is performed. 
However, there are no recommendations on immedi-
ate postoperative thromboprophylaxis after kidney tran-
splantation(6-8). Guideline recommendations and stand-
ardized protocols for the use of anticoagulation after 
kidney transplantation in APS patients should be de-
veloped.
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